$1.600
+0.235 (+14.70%)Al cierre
Comparativa sectorial de NRSN
In the context of the broader market, NRSN competes directly with industry leaders such as ERNA and KALA. With a market capitalization of $3.04M, it holds a significant position in the sector. When comparing efficiency, NRSN's gross margin of N/A stands against ERNA's N/A and KALA's N/A. Such benchmarking helps identify whether Neurosense Therapeutics Ltd is trading at a premium or discount relative to its financial performance.
Desempeño financiero de Neurosense Therapeutics Ltd
Neurosense has reported consistent net losses, with a net income of -3.56 million in the first half of 2026, indicating ongoing financial struggles. The current ratio has dropped to 0.28, highlighting liquidity issues.
Financials
Artículos relacionados
- Are You Buying NVIDIA’s Earnings or Its CEO’s Perfect Image?An Alphio analysis of NVIDIA’s share-price timeline, operating results, governance uncertainty and upcoming earnings.
- Stock Market After the 2026 Midterms: What a Democratic Congress Means for InvestorsDemocrats swept Congress in the 2026 midterms. See how stocks reacted, what history says about post-midterm returns, and which sectors face new risks.
- How to Rebalance a Concentrated Stock Portfolio in 2026: Mag7 Drift, Tax-Aware Trims, and Practical Rebalance a concentrated stock portfolio in 2026: Mag7 drift risk, 5pp bands, tax-aware trims, RSP/IWM diversifiers, and single-name caps.
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.